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Epstein–Barr virus (EBV) causes infectious mononucleosis and is
associated with cancers in immunocompromised populations. An-
tiviral drugs targeted against lytic viral replication have limited
efficacy in these disease settings. EBV infection of peripheral blood
mononuclear cells induces growth proliferation and the EBV la-
tency Epstein–Barr virus-encoded nuclear antigen (EBNA)2 tran-
scriptional transactivator (TAT) is essential for this response.
EBNA2 targets the cellular DNA-binding protein CBF1 to mimic
activated Notch signaling. A 10-aa peptide from the CBF1 interac-
tion domain of EBNA2 was synthesized as a fusion with the protein
transduction domain of HIV-1 TAT. The EBNA2-TAT peptide blocked
EBNA2-CBF1 interaction in an in vitro GST affinity assay and
labeling with fluorescein confirmed that the EBNA2-TAT peptide
efficiently entered cultured B cells. Neither EBNA2-TAT, nor a
mutant peptide with a 2-aa substitution that was unable to block
the EBNA2–CBF1 interaction, significantly affected the growth of
non-EBNA2-expressing EBV() B cells or Burkitt’s lymphoma Akata
cells. However, treatment of an EBV-immortalized lymphoblastoid
cell line with the EBNA2-TAT peptide stopped cell growth and
reduced cell viability. RT-PCR analyses of gene expression in the
peptide-treated lymphoblastoid cell line cultures revealed that
EBNA2-TAT treatment down-regulated the EBNA2-responsive viral
LMP1 and LMP2 genes and cellular CD23, intercellular adhesion
molecule 1, BATF, and Cdk1 genes while up-regulating expression
of the cyclin-dependent kinase inhibitor p21. EBV-induced out-
growth of B cells from cultured peripheral blood mononuclear cells
was also blocked in a dose-responsive manner by the EBNA2-TAT
peptide. This study suggests that cell-permeable EBNA2 peptides
may have potential as novel anti-EBV therapeutics.
Infection with Epstein–Barr virus (EBV) can have a wide rangeof health consequences, from inapparent, when the individual
is infected in childhood, to temporarily disabling, in the case of
infectious mononucleosis in young adults, to the rarer but graver
outcome of EBV-associated malignancy. Pathogenesis is pre-
dominantly associated with the proliferation of latently infected
cells and EBV encodes multiple genes that together orchestrate
this response. The full growth proliferative program, also called
latency III, comprises the nuclear proteins EBV-encoded nu-
clear antigens (EBNA)1, EBNA2, EBNA3A, -3B, and -3C, and
EBNA-LP, plus the latent membrane protein (LMP)1 and
LMP2A, the products of the BamHII-A rightward transcripts,
and the noncoding polymerase III EBER RNAs (1). This
program is expressed in in vitro EBV-infected lymphoblastoid
cell lines (LCLs), in naive B cells in the tonsils of healthy carriers
(2, 3), in the peripheral blood mononuclear cells (PBMCs) of
patients with mononucleosis (4), and in malignancies arising in
situations of immunocompromise, such as posttransplant (5–7)-
and AIDS-related malignancies (8, 9), as well as in lymphoma in
the aged (10). A more restricted pattern of EBV gene expression,
latency I or latency II, occurs in tumors arising in immunocom-
petent individuals. A feature of latencies I and II is the lack of
expression of EBNA2, one consequence of which is a loss of
expression of immunodominant viral epitopes (11).
EBNA2 is essential for EBV-immortalization of B cells and
contributes to the process as a transcriptional activator and a
mediator of cell survival. In both of these roles, EBNA2 mimics
aspects of activated Notch signaling (12–16). EBNA2 is one of the
first viral genes expressed after infection and regulates the expres-
sion of the other EBNA and LMP genes as well as reprogramming
cell gene expression. Like activated Notch, EBNA2 targets respon-
sive promoters predominantly through interaction with the CSL
family [CBF1, Su(H), Lag-1] DNA-binding protein CBF1 (17–20)
with additional interactions with proteins such as SpiPu.1 (21, 22),
AUF1 (23), SKIP (24), DP103 (25), the SWISNF complex (26),
and histone acetyl transferases (27) also influencing promoter
responsiveness. The critical importance of the EBNA2–CBF1
interaction is highlighted by the observation that EBV carrying a
mutated EBNA2 unable to bind CBF1 is incapable of immortal-
izing B cells (28). The antiapoptotic function shared by EBNA2 and
activated Notch is mediated through binding to the immediate-early
response factor Nur77 and prevention of Nur77-induced cell death
(29, 30).
The dependence on CBF1 as a partner for EBNA2 promoter
targeting raises the possibility that pharmacological disruption
of their interaction might represent a way to impact on the B cell
growth proliferative response induced by latent EBV infection.
Comparative protein sequence analysis revealed several short
amino acid sequences within the EBNA2–CBF1 interaction
domain that are highly conserved across the different EBV
strains and EBV-related lymphocryptoviruses (31–33). In earlier
work, peptides representing these conserved sequences were
tested as competitors for EBNA2 binding by using an in vitro
EMSA assay. A 10-aa peptide was identified that was an effective
competitor for EBNA2 binding to CBF1. A version of this
peptide in which the two tryptophan residues were changed to
serine and arginine did not affect the interaction (34). However,
assessing the potential of this reagent to disrupt EBNA2 function
in EBV-infected cells requires a means of delivering the peptide
across the cell plasma membrane and into the nucleus.
Recently, short basic regions termed protein transduction
domains (PTDs) have been identified and shown to be able to
transport linked cargo such as peptides, proteins, or nucleic acid
into living cells (35–37). Three proteins that contain PTDs are
HIV transcriptional transactivator (TAT), Drosophila antenna-
pedia, and herpes simplex virus VP22 (38–41). A synthetic
oligoarginine peptide also acts as an effective PTD (42–44). We
generated an EBNA2-TAT PTD peptide and tested this reagent
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for its ability to enter B cells and to affect B cell outgrowth
induced by EBV infection. The peptide had minimal toxicity
even at high concentration and antagonized EBNA2 activity in
both established EBV LCL cell lines and in primary B cell
outgrowth assays. The results suggest that, with further devel-
opment, PTD-based peptides may have therapeutic potential as
anti-EBV reagents in situations of immunocompromise or se-
vere acute disease where the EBV growth proliferative program
places the individual at risk for subsequent development of
EBV-associated malignancies.
Materials and Methods
Peptide Synthesis and Detection. Peptides were synthesized by
standard fluorenylmethoxycarbonyl methodology, were purified
by RP-HPLC, and were analyzed by MS. Concentrations were
based on peptide mass. An N-terminal aminohexanoic acid
linker to fluorescein was incorporated to reduce intramolecular
interactions.
Intracellular localization of an N-terminal f luorescein-
conjugated version of the EBNA2-TAT peptide (F-EBNA2-
TAT) was performed by pulsing the cells with 100 M peptide
in PBS, pH 7.4, plus 2% FCS for 20 min at room temperature.
The cells were then washed with PBS, were resuspended in 50 l
of PBS, were spotted onto slides, were fixed in 4% paraformal-
dehyde, were mounted with 4,6-diamidino-2-phenylindole
(Vector Laboratories), and were imaged by using a fluorescence
microscope.
For cellular uptake and stability, the cells were pulsed with 50
M peptide in RPMI medium 1640 with 10% FCS, were washed
with PBS, were lysed in Tris-tricine loading buffer [1 M TrisHCl
(pH 6.8)40% (volvol) glycerol14% (wtwt) SDS0.3 M
DTT0.06% (wtvol) Coomassie blue stain], were normalized by
a BCA protein assay (Pierce), and were run on a 10% Tris-tricine
gel. Peptide levels were imaged and quantitated with FluorChem
(Alpha Innotech, San Leandro, CA).
GST Affinity Assay. In vitro transcriptiontranslation of CBF1 was
carried out by using a TNT T7 quick-coupled transcription
translation system (Promega) and the plasmid pSG5-CBF1
(JH261). GST-tagged EBNA2 (252–425) (PDL115) was prepared
by standard procedures. Purified GST-EBNA2 (252–425) was
incubated with 2 l of 35S-labeled CBF1 in the absence or presence
of competitor EBNA2-TAT peptides at 0.1, 1, 10 or 100 g for 1 h
at room temperature. The beads were washed three times in NETN
buffer [100 mM NaCl1 mM EDTA0.2% Nonidet P-4020 mM
TrisHCl (pH 8.0)0.2 mM PMSF], and was added to 30 l of
sample buffer. Samples were boiled and electrophoresed through
SDS12% PAGE gels, which were dried and exposed to x-ray film.
Images were quantitated with FluorChem (Alpha Innotech).
Growth and Survival Assays. DG75, Akata, and an Akata virus-
immortalized LCL were fed daily with fresh medium or medium
containing peptide. Cell viability was determined by using
Trypan blue exclusion, and metabolic activity was measured by
using the CellTiter-Glo (Promega) assay.
Proliferation Assays. The EBV virus was obtained by treating
Akata or Akata Bx1 cells [gift of L. Hutt-Fletcher (Feist–Weiller
Cancer Center, Louisiana State University Health Sciences
Center, Shreveport, LA) (45) with 50 gml anti-IgG (Cappel)].
Virus supernatant was concentrated by using Centricon Plus-80
filters (Millipore). PBMCs (Johns Hopkins Oncology Center
Cell Procurement Bank) were infected with concentrated virus
for 3 h and were cultured in RPMI medium 1640 plus 10% FCS
for 7 days. Medium, plus or minus peptide, was replaced daily.
Assays were performed in 5- or 10-well replicates. Colony
outgrowth and EBV-GFP() cells were monitored by using
fluorescence microscopy. For fluorescence-activated cell sorter
analysis, PBMCs were incubated with anti-CD19 phycoerythrin-
conjugated antibody (Becton Dickinson Pharmingen).
RNA Extraction and RT-PCR. RNA was extracted from untreated
and peptide-treated LCLs by using RNeasy (Qiagen, Valencia,
CA). RNA was treated with Dnase (Invitrogen) according to
manufacturer’s instructions. cDNA synthesis was carried out
with AMV RT (Promega). PCR conditions were 2 min at 95°C,
30 sec at 55°C, 30 sec at 72°C, 30 sec at 95°C for 35 cycles, then
for 10 min at 72°C. The following PCR primers were used: LMP1
5-GTGATTCTGACGAAGCCAGAG-3 and 5-CGT-
GGGGCGCCCCAGGCACCA-3; LMP2A 5-GACTAT-
CAACCACTAGGAAC-3 and 5-CTGCCAAGAGTA-
GAAGTGAG-3; CD23 5-GTTGTCAGGGAGTGAGTGC-3
and 5-GCTCGAAGTTCCTCCAGTTC-3; cyclin-dependent
kinase (Cdk)1 5-GGCTCTTGGAAATTGAGCGGA-3 and
5-AGGAACCCCTTCCTCTTCACT-3; BATF 5-GACAA-
GAGAGCCCAGAGGTG-3 and 5-GTAGAGCCGCGTTCT-
GTTTC-3; p21 5-GTCCGTCAGAACCCATGCGGC-3 and
5-TGACAGGTCCACATGGTCTTC-3; intercellular adhe-
sion molecule 1 (ICAM-1) 5-GTAATACTGGGGAACCA-
GAG-3 and 5-GTCTCCTCGGTCCCTTCTGAG-3; -actin
5-TTGGCCTTGGGGTTCAGGGGGG-3 and 5-ATG-
GAACGCGACCTTGAGAG-3; and TATA box-binding pro-
tein 5-CACGAACCACGGCACTGATT-3 and 5-TTTTCT-
TGCTGCCAGTCTGGAC-3.
Southern blots were performed to confirm the specificity of
the RT-PCR products by using the following oligonucleotide
probes: LMP1 5-GTCTCCTCGGTCCCTTCTGAG-3;
LMP2A 5-GGTCACAACGGTACTAACTG-3; CD23 5-
CATCGGGAGAATCCAAGCAG-3; and Cdk1 5-CTAC-
CATACCCATTGACTAAC-3.
Results
Synthesis of EBNA2-TAT Peptides. Previously (34), we had identified
a peptide sequence from conserved region 6 of EBNA2, which
blocked interaction in vitro between viral EBNA2 and the
cellular protein CBF1 that targets EBNA2 to responsive pro-
moters. We wished to determine whether this peptide would be
capable of interfering with EBNA2 function in EBV-infected
cells. However, such an analysis requires that the peptide be
delivered across the cell membrane and into living B cells. We
synthesized the EBNA2 peptide as a fusion with TAT amino acid
47–57 (35) (PSGPPWWPPV-YGRKKRRQRRR). Two control
peptides were also synthesized; F-EBNA2-TAT, in which a
fluorescein moiety was conjugated through an aminohexanoate
linker and an EBNA2-TAT fusion in which the two tryptophans
in the EBNA2 peptide were changed to serine and arginine to
generate a mutant peptide [EBNA2(mt)-TAT] (PSGPPSRPPV-
YGRKKRRQRRR). HPLC analysis revealed a single peptide
species in each case and MS analysis confirmed the identity of
the peptides (data not shown).
To verify that the addition of a TAT fusion partner did not
alter the ability of the EBNA2 peptide to interfere with EBNA2
binding to CBF1, a GST affinity assay was performed and the
EBNA2-TAT peptide and EBNA2(mt)-TAT peptides were
tested as competitors. The CBF1-binding domain of EBNA2,
was expressed as a GST fusion protein, GST-EBNA2 (252–425),
and interaction between GST-EBNA2 (252–425) and in vitro-
translated 35S-labeled CBF1 was demonstrated (Fig. 1A). Added
EBNA2-TAT peptide was able to compete with 35S-labeled
CBF1 for binding to GST-EBNA2 (252–425) with an IC50 of
10 M, whereas the control EBNA2(mt)-TAT peptide was an
ineffective competitor.
EBNA2-TAT Peptide Uptake and Stability. To monitor uptake, the
fluorescein modified peptide F-EBNA2-TAT was incubated
with EBV() DG75 B cells for 20 min after which the cells were
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washed, spotted onto slides, fixed, and examined by fluorescence
microscopy (Fig. 1B). Uptake was very efficient, with essentially
all cells showing fluorescence throughout both the cytoplasm
and the nucleus. The time course of uptake of the F-EBNA2-
TAT peptide was examined in EBV() DG75 B cells. The
intracellular concentration of F-EBNA2-TAT peptide was mea-
sured by harvesting cells at the indicated times after peptide
exposure and subjecting the cell extracts to gel electrophoretic
separation. The relative amount of intracellular peptide was
quantified by using FluorChem to measure the fluorescence
intensity in the peptide band. Half-maximal peptide uptake
occurred at15 min after exposure to the cells at 37°C (Fig. 1C).
In the same way, we examined the stability of the peptide in
DG75 cells continuously exposed to peptide. An effective half-
life of 24 h was observed for the intracellular peptide (Fig. 1D).
EBNA2-TAT Peptide Affects the Growth and Survival of EBNA2-
Expressing LCLs. The effect of different concentrations of
EBNA2-TAT and EBNA2(mt)-TAT peptides on the growth of
EBV() and EBV() B cell lines was next examined. Over a
4-day period, treatment of EBV() DG75 cells with either
peptide at 1-, 25-, or 50-M concentrations had little effect on
cell proliferation (Fig. 2 A and B). Akata cells, which are
EBV() but are EBNA2(), were also not significantly affected
by treatment with either peptide (Fig. 2 C and D). A newly
established EBV LCL cell line was also insensitive to treatment
with mutant peptide at the same three concentrations (Fig. 2F).
However, treatment with wild-type EBNA2-TAT peptide at 25-
or 50-M concentrations dramatically reduced proliferation of
the LCL cells (Fig. 2E). The metabolic activity of LCLs treated
with 25 M EBNA2-TAT or EBNA2(mt)-TAT peptides was
examined in a CellTiter-Glo assay in which intracellular ATP
levels are measured by using a luciferase readout. Cells treated
with EBNA2-TAT peptide had significantly reduced metabolic
activity at both 24 and 48 h after treatment (Fig. 2G). In contrast,
cells treated with mutant peptide showed metabolic activity
comparable to controls in this assay (Fig. 2G). EBV LCLs have
up-regulated surface adhesion molecules and form macroscopic
clumps in culture. Examination of the peptide treated versus the
untreated LCL cultures revealed that the EBNA2(mt)-TAT
peptide did not affect this growth phenotype, whereas in the
EBNA2-TAT peptide-treated culture, the clumps were com-
pletely dispersed (Fig. 2H).
In culture, EBV() LCLs express the type III latency genes,
which include the membrane proteins LMP1 and LMP2A (1).
LMP1 is particularly important for cellular proliferative re-
sponses and is also responsible for the up-regulation of cell
adhesion antigens (46). Because LMP1 and LMP2A expression
in B cells is driven by EBNA2, we examined the effect of the
EBNA2-TAT peptides on their expression by using RT-PCR,
followed by Southern blotting of the PCR products. LCLs were
treated with 50-M concentrations of either wild-type or mutant
peptide for 24 and 48 h. Treatment with EBNA2-TAT peptide
significantly reduced the level of both transcripts at 48 h, whereas
treatment with mutant peptide did not alter transcript abun-
dance (Fig. 3A). EBNA2 also modulates cellular gene expression
and cell genes known to be EBNA2-responsive include CD23
and Cdk1. These genes were also expressed at reduced levels in
EBNA2-TAT peptide-treated LCLs (Fig. 3A). RNA expression
in peptide-treated cells was also examined by real-time RT-PCR
(Fig. 3B). LMP1, CD23, and Cdk1 were down-regulated in this
analysis, as was BATF and ICAM-1. In contrast, expression of
p21 was increased in peptide-treated cells at both 24 and 48 h.
EBNA2-TAT Peptide Blocks Outgrowth of Colonies from EBV-Infected
PBMCs. The EBNA2-TAT peptide interfered with the prolifer-
ation of already immortalized B cells that depended on the type
III latency program for continued growth. To evaluate the ability
of the EBNA2-TAT peptide to prevent EBV-induced initiation
of B cell proliferation, a PBMC proliferation assay was estab-
lished. Human PBMCs were incubated in the presence or
absence of EBV virus obtained from induced Akata BX-1 cells.
This virus contains a GFP marker inserted in the BXLF1 ORF
(45). After 7 days of incubation, the wells were examined for
outgrowth of clumps of self-adherent proliferating cells. In wells
that were left uninfected, most of the cells were dying and no
macroscopic colonies were visible. In contrast, wells that were
infected with EBV virus contained large numbers of macro-
scopic colonies that were GFP(), demonstrating EBV infection
(data not shown). The effect of the EBNA2-TAT and
EBNA2(mt)-TAT peptides on B cell outgrowth was assessed by
using 1-, 10-, and 50-M concentrations of peptide. The peptide
was added immediately after virus infection and replenished
daily. The EBNA2(mt)-TAT peptide had no discernable effect
on B cell colony outgrowth at any of the three doses, and in each
case, five of five wells contained macroscopic B cell colonies
(Fig. 4A). On the other hand, the EBNA2-TAT peptide had a
dose-responsive effect on colony formation. At the lowest con-
centration (1 M), four of five wells contained visible colonies;
at 10M, only one of five wells was positive and no colonies were
detected in the wells receiving 50M EBNA2-TAT peptide (Fig.
4A). The IC50 of the EBNA2-TAT peptide was 10 M, which
is consistent with the concentration required to block the
interaction of EBNA2 and CBF1 in a GST affinity assay (Fig.
1A).
To verify that the assay was measuring B cell outgrowth,
untreated PBMCs were taken at day 0 and at 7 days after EBV
infection, and were analyzed by fluorescence-activated cell
sorter for expression of the pan B cell marker CD19 (Fig. 4B).
Fig. 1. Peptide in vitro activity and intracellular availability. (A) GST affinity
assay in which in vitro-translated, 35S-labeled CBF1 (arrows) was incubated
with GST-EBNA2 (252–425) or control GST protein and binding was examined
in the presence of increasing amounts (0.125, 1.25, 12.5, and 125 M) of
competitor EBNA2-TAT (Upper) or EBNA2(mt)-TAT peptide (Lower). (B) Pho-
tomicrographs demonstrating incorporation of F-EBNA2-TAT into DG75 B
cells after 20 min of peptide exposure at room temperature. (Left Upper)
Fluorescein. (Right Upper) Cell nuclei stained with 4,6-diamidino-2-
phenylindole. (Lower) Confocal image of a single cell showing nuclear plus
cytoplasmic distribution of F-EBNA2-TAT (Left) and 4,6-diamidino-2-
phenylindole nuclear staining (Right). (C) Time course of F-EBNA2-TAT pep-
tide uptake into DG75 cells incubated with F-EBNA2-TAT peptide for the
indicated times. Intracellular F-EBNA2-TAT peptide levels were measured as
described in D. (D) F-EBNA2-TAT peptide bioavailability in DG75 cell cultures
incubated in medium containing 50 M peptide added at time 0. (Upper)
Visualization, by UV excitation, of electrophoretically separated intracellular
peptide. (Lower) Time course of loss of intracellular F-EBNA2-TAT peptide.
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At day 0, the PBMCs contained 5% CD19() B cells. By day 7
after EBV infection, 70% of the live cells were CD19().
Continuous Peptide Exposure Is Necessary to Prevent Colony Out-
growth. The EBNA2-TAT peptide is proposed to function by
competing with EBNA2 for CBF1 binding, and hence, down-
regulating EBNA2-responsive viral and cellular genes whose
expression is necessary for the growth proliferative response.
Such a mechanism of physical interference should require the
continuous presence of the peptide. The effect on B cell out-
growth of a regimen of short-term exposure followed by culture
in the absence of EBNA2-TAT peptide was therefore examined.
In this experiment, 10-well replicates were scored for macro-
scopic colony outgrowth. The peptide-treated wells were incu-
bated in medium containing EBNA2-TAT peptide at 10- or
100-M concentrations for 1 week after which the cultures were
switched to peptide free medium for another 3 weeks. No colony
outgrowth was detected in the uninfected PBMC cultures at any
of the time points examined (1, 3, and 4 weeks), whereas the
EBV-infected wells all contained macroscopic colonies (Table
1). In the wells treated with the EBNA2-TAT peptide, no colony
outgrowth was visible after 1 week of continuous treatment with
either 10- or 100-M peptide concentrations. However, when the
cultures were maintained for another 3 weeks in the absence of
peptide, colony outgrowth rebounded. Ten of 10 wells treated
initially with 10 M EBNA2-TAT peptide and 8 of 10 wells
treated initially with 100 M EBNA2-TAT peptide contained
macroscopic colonies at the 4-week postinfection time point.
This result indicates that continuous exposure to peptide is
needed to interfere with EBNA2 function and provides addi-
tional support for the proposed mechanism of action of the
EBNA2-TAT peptide.
Discussion
PTDs have the ability to mediate cell entry in a concentration-
dependent manner that is independent of receptors or trans-
porters and consequently operates in a wide variety of cell types.
The mechanism of cell entry is not fully understood but may
involve avid binding of the positively charged residues to cell-
surface polyanions such as heparin sulfate and internalization
through an endocytosis related process (35, 47). PTDs have been
used to deliver fusion proteins and peptides that have shown
biological activity (48–58). The EBNA2-TAT peptide severely
impaired the growth of cultured EBV() LCLs. The LCL
cultures used in our experiments were newly immortalized and
the W latency promoter was still active (data not shown). The W
latency promoter is not CBF1- or EBNA2-responsive and hence
W latency promoter-driven EBNA2 expression would not be
affected by the EBNA2-TAT peptide. The use of newly immor-
talized LCLs in these experiments allowed us to evaluate the
impact of interfering with EBNA2 activation of CBF1-
responsive promoters in a setting in which normal EBNA2
expression was retained. This result differs from previous anal-
yses of EBNA2 function that have studied the effects of loss of
EBNA2 through genetic deletion or through conditional nuclear
localization.
LCLs are dependent on the transcriptional activation function
of EBNA2 for continued growth. LCLs immortalized with a
virus expressing an estrogen-regulated EBNA2 stop growing
when estrogen is removed from the culture medium (59). These
cells can be rescued by transduction with a vector expressing
Fig. 2. EBNA2-TAT affects EBNA2() LCL growth and metabolic activity. Proliferation assays showing the effect of EBNA2-TAT (A, C, and E) and EBNA2(mt)-TAT
(B, D, and F) peptides on cell growth. X, Untreated; , 1 M peptide; , 25 M peptide; ‚, 50 M peptide. Neither EBNA2-TAT nor EBNA2(mt)-TAT peptide
significantly affected growth of EBV() DG75 B cells (A and B) or EBV(), but EBNA2() Akata cells (C and D). Growth of EBV and EBNA2() LCLs was inhibited
by EBNA2-TAT peptide at 25- and 50-M concentrations (E) but not by EBNA2(mt)-TAT peptide (F). (G) Comparison of the metabolic activity of EBV LCLs
untreated or treated for 24 or 48 h with 25 M EBNA2-TAT or EBNA2(mt)-TAT peptide. Metabolic activity, as measured in a CellTiter-Glo assay, was drastically
reduced by EBNA2-TAT treatment. Filled bars, untreated; open bars, 25 mM EBNA2-TAT; shaded bars, 25 M EBNA2(mt)-TAT. (H) Phase contrast photomicro-
graphs of EBV LCLs showing that EBNA2-TAT, but not EBNA2(mt)-TAT, at a concentration of 50 M, prevents LCLs from growing as macroscopic colonies. U,
untreated; wt, EBNA2-TAT 50 mM; mt, EBNA2(mt)-TAT 50 mM.
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wild-type EBNA2, but cannot be rescued by an EBNA2 that is
mutated in the conserved region 6 motif and is unable to interact
with CBF1 (13). The estrogen-regulated LCLs can also be
rescued by transduction of activated intracellular domain of
Notch (NotchIC) in circumstances in which LMP1 is either also
provided or is selectively up-regulated (13, 14, 60). This obser-
vation highlights both the high degree of overlap in EBNA2- and
NotchIC-regulated cell genes and the importance for B cell
growth of EBNA2 activation of the viral LMP1 gene (which is
poorly responsive to NotchIC). RT-PCR analyses revealed that
LMP1 was down regulated by the EBNA2-TAT peptide and this
is likely to be a significant component of the EBNA2-TAT
peptide’s negative effect on LCL growth. Although EBNA2 and
NotchIC both alter cellular gene expression through interactions
with CBF1, the EBNA2-TAT peptide is designed to be specific
for the EBNA2–CBF1 interaction. EBNA2 and NotchIC bind to
adjacent but distinct regions of CBF1, and mutagenesis studies
have identified amino acids that affect only NotchIC or EBNA2
interaction (61, 62).
The EBNA2-regulated viral LMP2A gene also showed re-
duced expression in the presence of the EBNA2-TAT peptide.
LMP2A inhibits lytic viral reactivation and provides cell survival
signals through activation of Akt (63, 64). Cell genes tested that
were known to be either EBNA2-regulated or responsive to the
combination of EBNA2 and LMP1 were also down-regulated in
the presence of the EBNA2-TAT peptide. ICAM-1 (65) medi-
ates cell–cell contacts and contributes to B cell growth as clumps
in culture, soluble CD23 (46) acts as an autocrine growth factor,
and BATF (66), an AP-1 family member, may have a role in
repression of the EBV lytic cycle. Cdk1Cdc2 (59) interacts with
A and B cyclins to regulate the mitotic phase of the cell cycle (67)
and was the most significantly affected of the cellular genes
evaluated here. The Cdk1 promoter is regulated by nuclear
factor Y, and nuclear factor Y has recently been found to be
up-regulated by EBNA2 in conditionally EBNA2-expressing
cells (68). With the exception of Cdk1, the real-time RT-PCR
analyses showed a relatively small down-regulation of the tested
genes by the EBNA2-TAT peptide. This observation suggests
that cessation of EBV-driven LCL growth can be achieved
through the accumulated effects of down-regulating multiple
genes without necessarily completely ablating expression of
individual EBNA2-regulated genes. The increased expression of
p21 observed in the peptide treated cells is consistent with
induction of growth arrest.
The EBNA2-TAT peptide also prevented the proliferation of
primary B cells infected in vitro with EBV. The effect was specific
in that the EBNA2(mt)-TAT peptide did not have this property
and continuous exposure to peptide was required to block
outgrowth of proliferating B cell colonies. Improved bioavail-
ability of the peptide could be addressed in the future by using
peptidomimetic approaches or modifications such as cyclization.
Peptidomimetics contain nonnatural building blocks such as
D-amino acids or -amino acids (69–71). The ability of the
EBNA2-TAT peptide to affect the growth of EBV-infected
LCLs as well as to prevent expansion of newly infected B cells
suggests that the peptide may have therapeutic potential. Early-
onset posttransplant lymphoproliferative disease is strongly
EBV-associated and has a high mortality. The disease is a
Fig. 3. EBNA2-TAT down-regulates expression of known EBNA2-responsive
viral and cellular genes. (A) Southern blots of RT-PCR products amplified using
primers for the EBNA2-regulated EBV LMP1 and LMP2A genes and cell CD23
and Cdk1 genes. The amplified products were hybridized with 32P-labeled
oligonucleotide probes specific for the individual genes. Ethidium bromide-
stained -actin cDNA served as a loading control. U, untreated; wt, 50 mM
EBNA2-TAT; mt, 50 mM EBNA2(mt)-TAT. (B) Changes in gene expression in
peptide-treated LCLs as measured by real-time RT-PCR. Results are shown as
the relative fold difference between LCLs treated with 50 M EBNA2-TAT or
EBNA2 (mt)-TAT, with TATA box-binding protein as the internal standard.
Cells were treated for 24 h (open bar) or 48 h (filled bar). The data are
representative of three experiments.
Fig. 4. EBNA2-TAT prevents EBV-induced B cell proliferation. (A) Phase
contrast photomicrographs showing PBMC 7 days after EBV infection in the
presence of 1-, 10-, or 50-M concentrations of EBNA2-TAT or EBNA2(mt)-TAT
peptide. The infections were performed in five-well replicates. The fraction of
the wells showing B cell outgrowth is indicated. B cell outgrowth was not
affected by EBNA2(mt)-TAT but was reduced at 1- and 10-M EBNA2-TAT
concentrations and was abolished by 50 M EBNA2-TAT peptide. (B) Fluores-
cence-activated cell sorter profile showing that proliferating colonies are B
cells. Expression of the CD19 B cell marker at days 0 and 7 after EBV infection
is shown. Bar, CD19 cells.
Table 1. Continuous EBNA2-TAT is required to block EBV-induced
B cell proliferation
Experimental conditions
Colony outgrowth at
1 week 3 weeks 4 weeks
Infected 10 of 10 10 of 10 9 of 9
Uninfected 0 of 10 0 of 10 0 of 10
Infected, 10 M EBNA2-TAT* 0 of 10 0 of 10 10 of 10
Infected, 100 M EBNA2-TAT* 0 of 10 0 of 10 8 of 10
*Treated for 1 week.
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particular problem in children who are more likely to be
EBV-seronegative at the time of transplant (6). There is some
heterogeneity in viral gene expression in the tumor cells but
EBNA2-driven expansion is a significant component of the
disease. Current treatment centers on reduction in immunosup-
pression, which carries an associated risk of graft rejection.
Other treatments such as adoptive immunotherapy and clear-
ance of B cells by using anti-B cell antibodies show promise but
there remains a need for additional treatment options (72).
Infectious mononucleosis normally resolves with only symptom-
atic treatment. However, infectious mononucleosis can have an
extended recovery time in severe cases and new intervention
strategies targeting the expansion of latently infected cells may
also be relevant to primary EBV-associated disease.
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